propane-2-sulfonic acid piperidide | 144091-30-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: propane-2-sulfonic acid piperidide
• 英文别名: 1-Propan-2-ylsulfonylpiperidine
• CAS: 144091-30-5
• 化学式: C₈H₁₇NO₂S
• 分子量: 191.294
• InChiKey: BMRHKOJWCCHOEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  哌啶 、 异丙基磺酰氯 以 乙醚 为溶剂， 反应 0.17h， 以7.4 g的产率得到propane-2-sulfonic acid piperidide
  参考文献：
  名称：

  Studies on the base-catalyzed Solvolysis of Propane-2-sulphonic Acid p-Cresylester

  摘要：

  Products of the reaction of propane-2-sulphonic acid p-cresylester with sodium butoxide in butanol are the sodium salt of propan-2-sulphonic acid, di-n-butyl ether, p-cresyl-n-butyl ether and p-cresol. The reaction proceeds via propane-2-sulphonic acid n-butylester which is formed from the starting compound by an elimination-addition (sulphene) mechanism. The elimination step is an E1-cB reaction.

  DOI：

  10.1002/prac.19923340310

文献信息

• HPK1 ANTAGONISTS AND USES THEREOF
  申请人：Nimbus Saturn, Inc.

  公开号：US20210078996A1

  公开（公告）日：2021-03-18

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物用于抑制HPK1和治疗HPK1介导的疾病的方法。
• METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS
  申请人：Polniaszek Richard

  公开号：US20100256366A1

  公开（公告）日：2010-10-07

  The invention provides methods and intermediates that are useful for preparing a compound of formula I: and salts thereof.

  本发明提供了用于制备公式I化合物的有用方法和中间体： 及其盐类。
• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
  申请人：Rodgers D. James

  公开号：US20070135461A1

  公开（公告）日：2007-06-14

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶，可以调节雅努斯激酶的活性，并且在治疗与雅努斯激酶活性相关的疾病中具有用处，例如免疫相关疾病、皮肤疾病、髓增生性疾病、癌症和其他疾病。
• HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center

  公开号：US20140057914A1

  公开（公告）日：2014-02-27

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

  本发明涉及化合物和方法，可能用作HIF通路活性的抑制剂，用于治疗或预防癌症和其他缺氧介导的疾病。
• SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Board of Regents, University of Texas System

  公开号：US20150239876A1

  公开（公告）日：2015-08-27

  The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

  本公开涉及杂环化合物的盐和抑制HIF通路活性的方法。这些化合物被设计用于治疗或预防癌症和其他缺氧介导的疾病。